Diabetic Nephropathy Research Articles

Aberrant N-glycation of Complement Factor H Contributes to Alternative Pathway Activation and Disease Progression in Diabetic Kidney Disease

Aberrant N-glycation of Complement Factor H Contributes to Alternative Pathway Activation and Disease Progression in Diabetic Kidney Disease

Urinary Growth Differentiation Factor 15 May Be a New Biomarker of Kidney Failure Progression in Diabetic Kidney Disease

Urinary Growth Differentiation Factor 15 May Be a New Biomarker of Kidney Failure Progression in Diabetic Kidney Disease

Deletion of Angiotensinogen in Renal Tubules Attenuates Tubular Senescence in Diabetic Kidney Disease

Deletion of Angiotensinogen in Renal Tubules Attenuates Tubular Senescence in Diabetic Kidney Disease

Clinical Characteristics of Nodular Lesions in Patients with Diabetic Kidney Disease

Clinical Characteristics of Nodular Lesions in Patients with Diabetic Kidney Disease

Associations of Kidney Dietary Adherence with Kidney Function among Veterans with Diabetic Kidney Disease

Associations of Kidney Dietary Adherence with Kidney Function among Veterans with Diabetic Kidney Disease

Identification of Circulating Microbial DNA and Its Correlation in Patients with Diabetic Kidney Disease

Identification of Circulating Microbial DNA and Its Correlation in Patients with Diabetic Kidney Disease

Pegloticase-Induced Rapid Uric Acid Lowering and Kidney and Cardiac Health Markers in Youth-Onset Type 2 Diabetes: A Pilot Clinical Trial

Rationale & ObjectiveElevated serum uric acid (SUA) is a risk factor for incident hypertension and diabetic kidney disease in young persons with type 2 diabetes (T2D), particularly men. The acute benefit of aggressively lowering SUA on kidney and cardiovascular function in this population remains underexplored. This study was conducted to investigate the impact of a single pegloticase infusion on kidney and cardiovascular function. Study DesignAn open-label pilot trial. Setting & ParticipantsThe study involved 10 young adult males with youth-onset T2D and SUA levels ≥5 mg/dL. Intervention(s)Participants received a single infusion of pegloticase (8 mg). Evaluations were conducted using iohexol-based measured glomerular filtration rate (mGFR) and cardiac/kidney MRI before and one week after infusion. OutcomesThe primary outcomes were changes in SUA and mGFR one week after pegloticase infusion. ResultsNine participants (mean [±SD] age 22±5 years, HbA1c 8.6±3.3%, BMI 40.1±11.0 kg/m2, SUA 6.7±1.1 mg/dL) completed the pegloticase infusion and were included in the analysis. One week after the infusion, median [p25,p75] SUA concentrations dropped from 6.4 [5.6,7.6] to 0.5 [0.5,4.6] mg/dL (p=0.01). Mean mGFR increased from 113±20 to 122±19 ml/min per 1.73 m2 (p=0.004). Among responders (SUA reduction ≥3 mg/dL), an increase in mGFR correlated with an increase in renal artery blood flow (r:0.60, p=0.24) and decrease in SUA (r:-0.79, p=0.05). Mean MRI peak longitudinal cardiac strain additionally decreased from 15.4±2.2 to 13.1±2.2 % (p=0.03) in these responders. LimitationsThe pilot nature of the study and the small sample size limit the generalizability of the findings. ConclusionsIn young adult males with T2D, a single pegloticase infusion decreased SUA levels, which increased mGFR and was strongly associated with increased renal blood flow and impaired cardiac global longitudinal strain. Further research is required to assess the long-term efficacy and safety of pegloticase in patients with T2D.

Symptoms and Impacts Experienced by People Living with Nondiabetic CKD (ndCKD) and Diabetic Kidney Disease (DKD): Qualitative Interview Findings

Symptoms and Impacts Experienced by People Living with Nondiabetic CKD (ndCKD) and Diabetic Kidney Disease (DKD): Qualitative Interview Findings

Young-onset type 2 diabetes mellitus enhances proteinuria, but not glomerular filtration rate decline: A Japanese cohort study.

The time course of chronic kidney disease in young-onset type 2 diabetes mellitus remains unclear. We compared the trajectories of proteinuria and estimated glomerular filtration rate (eGFR) decline between young-onset (aged ≤40 years) and late-onset (aged >40 years) type 2 diabetes mellitus in a Japanese multicenter cohort. Participants without diabetic kidney disease were divided into two groups according to age at diagnosis: young- and late-onset. The primary endpoint was eGFR <60 mL/min/1.73 m2, proteinuria or both. Multivariable Cox proportional hazards were calculated to estimate incidence. Among 626 participants with type 2 diabetes mellitus, 78 (12.4%) had young-onset and 548 (87.6%) had late-onset diabetes. The incidence of eGFR <60 mL/min/1.73 m2 was lower (16.7% vs 33.5%, P = 0.003), but that of proteinuria was higher (46.2% vs 28.9%, P = 0.002) in the young-onset type 2 diabetes mellitus group. The Kaplan-Meyer curve showed that young-onset type 2 diabetes mellitus was associated with a decreased hazard ratio (HR) for eGFR <60 mL/min/1.73 m2 and an increased HR for proteinuria compared with late-onset type 2 diabetes mellitus. In the multivariate Cox analysis, young-onset type 2 diabetes mellitus increased the HR (95% confidence interval) of proteinuria (1.53, 95% confidence interval 1.03-2.26), but did not change the eGFR <60 mL/min/1.73 m2 HR. Young-onset type 2 diabetes mellitus has a lower HR of eGFR <60 mL/min/1.73 m2 and an increased HR of proteinuria compared with late-onset type 2 diabetes mellitus, indicating that young-onset type 2 diabetes mellitus has a different time course for the development of proteinuria and subsequent eGFR decline.

Circulating Proteins Associated with Apoptosis Processes and Fast Progression to ESKD in Diabetic Kidney Disease

Circulating Proteins Associated with Apoptosis Processes and Fast Progression to ESKD in Diabetic Kidney Disease

Loss of Globotriaosylceramide Protects against Diabetic Kidney Disease

Loss of Globotriaosylceramide Protects against Diabetic Kidney Disease

Senolytics (Dasatinib/Quercetin) Inhibit Hedgehog Interacting Protein (Hhip)-Mediated Tubular Senescence in Diabetic Kidney Disease

Senolytics (Dasatinib/Quercetin) Inhibit Hedgehog Interacting Protein (Hhip)-Mediated Tubular Senescence in Diabetic Kidney Disease

PDK4/SMAD3/HIF-1α Circle Enhances AKI Susceptibility in Diabetic Kidney Disease (DKD) through Fibrosis

PDK4/SMAD3/HIF-1α Circle Enhances AKI Susceptibility in Diabetic Kidney Disease (DKD) through Fibrosis

Understanding the Protective Role of Podocyte-Specific ApoJ in Diabetic Kidney Disease

Understanding the Protective Role of Podocyte-Specific ApoJ in Diabetic Kidney Disease

Regional Differences in Kidney Replacement Therapy in Diabetic Kidney Disease: Apollo Dial DB

Regional Differences in Kidney Replacement Therapy in Diabetic Kidney Disease: Apollo Dial DB

IL-32 Is a Lipid Droplet-Associated Mediator of Tubular Injury in Diabetic Kidney Disease

IL-32 Is a Lipid Droplet-Associated Mediator of Tubular Injury in Diabetic Kidney Disease

STING-Dependent Podocyte Injury Is Associated with Impaired Mitophagy in Diabetic Kidney Disease (DKD)

STING-Dependent Podocyte Injury Is Associated with Impaired Mitophagy in Diabetic Kidney Disease (DKD)

Unraveling the Mechanism of SGLT2 Inhibitors Using Urinary Proteomics in Patients with Diabetic Kidney Disease

Unraveling the Mechanism of SGLT2 Inhibitors Using Urinary Proteomics in Patients with Diabetic Kidney Disease

SGLT2 Inhibition Alters Methionine Metabolism in Diabetic Kidney Disease

SGLT2 Inhibition Alters Methionine Metabolism in Diabetic Kidney Disease

Impact of Carbamylation on the Association of Glycated Albumin and Diabetic Kidney Disease (DKD) Progression

Impact of Carbamylation on the Association of Glycated Albumin and Diabetic Kidney Disease (DKD) Progression